A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)

Clinical trial NCT01713582 · COMPLETED

Trial details

NCT number: NCT01713582
Sponsor: Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Diffuse Large B-cell Lymphoma Acute Lymphoblastic Leukemia Multiple Myeloma

Start date: 2012-12-14
Primary completion: 2017-01-20
Enrollment: 141

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.